Skip to main content

Table 3 Factors affecting outcome of MC

From: Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

 

Improved (p value compared to worse)

Unchanged (p value compared to worse)

Worse

Female (% of patients)

51.5% (0.89#)

40.5% (0.62#)

48.1%

Age at MC [Year, mean (SD)]

57.9 (21.8) (0.01+)

60.7 (17.8) (0.14+)

67.5 (15.0)

Time between diagnosis and MC [Months, mean (SD)]

31.1 (50.7) (0.77+)

27.5 (61.0) (0.77+)

36.4 (52.5)

MGFA before MC [MGFA, median (IQR)]

2 (1) (0.006+)

2 (1) (0.38 +)

3 (2)

MGFA at admission [MGFA, median (IQR)]

3 (1) (< 0.001+)

3 (1) (0.008+)

4 (2)

Treated with IST at start of MD (% of patients)

63.1% (0.13#)

60.0% (0.49#)

50.9%

MC triggered by infection (% of MC triggered by infections)

33.5% (0.005#)

42.4% (0.26#)

56.6%

VC before MC [VC in ml, mean (SD)]

2192 (822) (0.14+)

1938 (739) (< 0.001+)

1533 (581)

VC at admission [VC in ml, mean (SD)]

1292 (800) (0.04+)

1263 (598) (0.006+)

871 (348)

Comorbidities [Number of comorbidities at admission, median (IQR)]

2 (2) (< 0.001+)

2 (2) (< 0.001+)

4 (2)

Time of hospitalisation [days, mean (SD)]

20.2 (16.1) (< 0.001+)

24.7 (25.8) (0.11+)

34.1 (32.4)

Intubated (% of patients)

26.9% (< 0.001#)

26.7% (0.002#)

64.2%

Time of invasive ventilation (days, mean)

7.8 (13.8) (0.002+)

4.1 (8.9) (0.001+)

22.6 (39.2)

Pneumonia (% of patients)

26.1% (< 0.001#)

20.0% (< 0.001#)

57.1%

Sepsis (% of patients)

6.6% (0.002#)

3.3% (0.013#)

25.0%

Treated with PLEX or IA (% of patients)

57.8% (0.11#)

45.5% (0.99#)

34.2%

Treated with IVIG and PLEX or IA (% of patients)

24.3% (0.24#)

12.2% (0.76#)

15.3%

Treated with no IVIG, PLEX or IA (% of patients)

18.0% (< 0.001#)

15.2% (< 0.001#)

60.3%

  1. Factors affecting the outcome of MC. SD standard deviation, IQR interquartile range, MC myasthenic crisis, MGFA Myasthenia Gravis Foundation of America, IST immunosuppressive therapy, IVIG intravenous immunoglobulin, IA immunoadsorption, PLEX plasmapheresis, VC vital capacity. Patients who died during the MC were excluded from the analysis as to prevent bias of data due to early death. Significance for groups was assessed by ANOVA (denoted by +) or Fisher’s exact test (denoted by #). To account for multiple comparisons, statistical significance was corrected by the false discovery rate (FDR). A p-value below 0.05 was considered statistically significant. Statistically significant results are bold. Unless otherwise specified, values are mean ± SD (range), median ± IQR (range) or n (%)